Type 2 diabetes treatments targeting the GLP-1 axis by either inhibiting its rapid clearance by dipeptidyl-peptidase IV or using GLP-1 mimetics are currently used. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.